The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.
Tag: Eisai Co Ltd
-
FDA Approves, Leqembi, New Treatment for Early Alzheimer’s
The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
-
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.
-
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing.